Bausch Health Reports Strong Q2 2025 Financial Results

Bausch Health Companies Inc. announced its Q2 2025 results, reporting consolidated revenues of $2.53 billion, a 5% increase from the previous year. The company's net income attributable to Bausch Health was $148 million, with consolidated adjusted EBITDA rising by 6% to $842 million.

Excluding Bausch + Lomb, the company registered its ninth consecutive quarter of growth, with revenues up by 5% and adjusted EBITDA by 10%. Bausch Health plans to repay approximately $900 million in debt post-quarter using cash reserves.

Additionally, Bausch Health agreed to acquire DURECT Corporation, aiming to leverage its hepatology expertise in alcohol-induced hepatitis treatments. The acquisition is pending closing conditions. Full-year 2025 guidance remains reaffirmed, projecting steady revenue and EBITDA growth.

Segment-wise, Salix reported a 12% revenue increase, driven by Xifaxan®, while Solta Medical saw a 25% boost. However, the Diversified segment faced a 13% decline. The Bausch + Lomb segment noted a 5% increase in revenues.